Medtronic talks diabetes group's FDA warning letter, new products, supply chain constraints

Medtronic talks diabetes group's FDA warning letter, new products, supply chain constraints

Source: 
Medtech Dive
snippet: 

Ali Dianaty, VP of product innovation & operations for Medtronic Diabetes, spoke to MedTech Dive about the warning letter's impact on product reviews, creating insulin pump patches and the pandemic.